Akero's lead drug helps improve scarring in fatty liver disease patients

Akero Therapeutics

04/03/2024 11:09

March 4 (Reuters) - Akero Therapeutics  AKRO.O  said on
Monday its lead experimental drug to treat a type of fatty liver
disease helped improve scarring in patients' organ after 96
weeks, meeting the main goal of a mid-stage study.
    Shares of the company soared 91% on the news.

 (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh
Kuber)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))